Brief: Mink Therapeutics Says Co Discussing Potential Combination Trials & Strategic Minority Investments
27/03/2026 15:28
March 27 (Reuters) - Mink Therapeutics Inc INKT.O: MINK THERAPEUTICS INC - IN DISCUSSIONS FOR POTENTIAL COMBINATION TRIALS AND STRATEGIC MINORITY INVESTMENTS - SEC FILING MINK THERAPEUTICS: IN DISCUSSIONS WITH MULTIPLE PARTIES REGARDING POTENTIAL COMBINATION TRIALS INVOLVING AGENT-797 MINK THERAPEUTICS INC - HAS NOT PUBLICLY DISCLOSED ANY BINDING ARRANGEMENTS FOR COMBINATION TRIALS OR STRATEGIC INVESTMENTS - SEC FILING Source text: [ID:n0001193125-26-127931] Further company coverage: INKT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mink Therapeutics
See all newsMiNK Therapeutics Q2 loss narrows on expense discipline
Brief: MiNK Therapeutics Q2 EPS USD -0.62
Mink Therapeutics Inc expected to post a loss of 60 cents a share - Earnings Preview
Brief: MiNK Therapeutics Says No Major Serious Adverse Events Attributed To Agent-797 In First Patients
U.S. STOCKS ON THE MOVE-Snowflake, Best Buy, Kohl's